Lazard Asset Management
SPRY icon

Lazard Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Lazard Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,347
Closed -$167K – 2069
2025
Q4 		$167K Buy
+14,347
New +$140K ﹤0.01% 1676

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lazard Asset Management's SPRY Position: Q1 2026 in Review

Lazard Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 14,347 shares — an estimated $167K sold.

Lazard Asset Management first reported a position in SPRY in Q4 2025 and held it in 1 quarter. The position peaked at $167K in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Lazard Asset Management reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 14,347 ARS Pharmaceuticals shares in Q1 2026, an estimated $167K.
  • Lazard Asset Management first reported a position in ARS Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Lazard Asset Management's ARS Pharmaceuticals position peaked at $167K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.